Introduction
============

Every year, 7 million lives are lost due to preventable and treatable cancers ([@B1]). Incidence rates of cancers could increase substantially in the future, with up to 15 million new cases in 2020, most of which will be in developing countries ([@B2]). Among all cancer types, gastric cancer (GC) is one of the leading causes of death in recent decades, and its death toll has been steadily increasing in Asia and across the globe ([@B3]). Environmental factors such as obesity and gastroesophageal reflux disease are thought to contribute to its deadliness ([@B4]). At diagnosis, 23% of GC cases are localized, 32% are detected in the lymph nodes, and 34% are metastatic ([@B5]). In localized cases, treatment usually involves a combination of surgery, radiation, and chemotherapy, supplemented with adjuvant therapy ([@B6], [@B7]).

Misdiagnosis is the greatest obstacle facing treatment of GC in Iran ([@B8]-[@B10]). In most cases, by the time the disease is detected and properly diagnosed, surgery is the only viable option. Therefore, early detection and screening programs are critical to improve prognoses in GC patients ([@B11], [@B12]). In the last decade, there are a growing number of Iranian studies, which have focused on the rate of GC survival. Results of these studies indicate that survival rates in Iran are consistent with those in other developing countries, but lower than those in developed countries ([@B13]).

It is difficult to conduct population-based cancer studies in Iran, due to incomplete hospital records, careless registration processes, insufficient training, haphazard patient follow-up policies, and a lack of regional and provincial cancer centers. Inconsistent GC survival rates are also a prevalent feature in Iranian medicine, the lowest and highest of which were 81% ([@B14]) and 21% ([@B15]), respectively, for one year, and 31% ([@B16]) and 5.4% ([@B17]), respectively, for five years.
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According to our research, no recent systematic review has focused on GC survival in Iran. The present study intends to contribute to the extant literature by providing a systematic review and meta-analysis of one- and five-year survival rates in Iranian GC patients, and performing subgroup analyses and meta-regression to explore possible sources of heterogeneity among included studies.

Methods
=======

Through an electronic and manual search, 102 papers were identified ([Table1](#T1){ref-type="table"}). After exclusion of reviews and duplicate articles, as well as title screen, 43 separate publications remained for further appraisal. Remained articles, subsequent to abstract and full text review we removed 17 publications according to exclusion criteria and in final data set consisted of 26 publications ([Figure 1](#F1){ref-type="fig"}). Interpretation results of [table 2](#T2){ref-type="table"} shows attention to survival rate in patients with GC in Iran is increasing as if (64.4%) of final articles were published in 2011 onwards. Hospital records were the primary data source for the greater part of studies (61.5%). The pooled participants in the study were 29361 patients with GC ([Table1](#T1){ref-type="table"}).

Twenty-four eligible papers including 28949 patients were included in meta-analysis to estimate of one-year survival rate. The overall one year survival rate in patients with GC in Iran was 0.52 (95% CI: 0.52 to 0.53). A significant heterogeneity among these studies was observed (heterogeneity statistic= 379.79, P\<.001, I^2^= 98.5%, 95% CI 97.4--99.8) (Figure 2).

For Meta-analysis of five-year survival rate twenty-two publications with 28268 patients were considered. The overall five year survival rate in patients with GC in Iran was 0.15 (95% CI: 0.15 to 0.16).

###### 

Feature and characteristic studies included in study

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref.\      First Author\          Years of flow\        No. of Patients   Data source                          Analysis                                                  Survival Rate (%)   Quality\*                  
  No.        (Year of Pub)          Sitting                                                                                                                                                                               
  ---------- ---------------------- --------------------- ----------------- ------------------------------------ --------------------------------------------------------- ------------------- ----------- ---- ---- ---- --------
  ([@B19])   Biglarian A\           2002-2007,\           436               Hospital records                     Cox proportional hazards                                  78                  53          41   32   17   High
             2011                   Tehran                                                                                                                                                                                

  ([@B20])   Mehrabian AA\          2001-2006, National   19537             Iran Cancer Registration\            Life time table                                           49                  29          23   23   15   High
             2010                                                           Center                                                                                                                                        

  ([@B16])   Soroush A\             2008-2010,            98                Hospital records                     Kaplan--Meier method and Cox proportional hazard models   60                                        31   High
             2013                                                                                                                                                                                                         

  ([@B21])   Zare A\                1995-1999,\           330               Iran Cancer Institute                Cox proportional hazards model                            66                  42          31   26   21   High
             2013                   National                                                                                                                                                                              

  ([@B22])   Baghestani AR\         2003-2008, Tehran     178               Hospital records                     Bayesian Weibull and Exponential models                   80                  52          35             High
             2009                                                                                                                                                                                                         

  ([@B23])   Moghimi-Dehkordi B\    2001-2006,\           746               Cancer Registry\                     life-table method and Wilcoxon (Gehan) test               73                  50          40   33   29   High
             2008                   Tehran                                  Center                                                                                                                                        

  ([@B24])   Samadi F\              2000-2004, Ardabil    279               Hospital records                     Kaplan--Meier method and Cox proportional hazard models   41                                        8    High
             2007                                                                                                                                                                                                         

  ([@B25])   Noorkojuri H\          2003-2008,\           216               Tehran Cancer Registry               Cox proportional hazards and smoothing methods            80                  56          40   35   30   High
             2013                   Tehean                                                                                                                                                                                

  ([@B26])   Yazdani-Charati J\     2007-2010, Sari       190               Hospital records                     Kaplan-Meier\                                             45                  26          8              High
             2014                                                                                                method                                                                                                   

  ([@B27])   Ghadimi Gh\            1990-199,\            484               Cancer Registration Center           Weibull, Log-normal, and the Log-logistic model           24                              16        15   High
             2011                   Babol                                                                                                                                                                                 

  ([@B28])   Maroufizadeh S\        2003-1008,\           213               Cancer Registration Center           Cox and Additive hazards models                           79                              35        14   High
             2011                   Tehean                                                                                                                                                                                

  ([@B15])   Bashash M,\            2004,\                261               population-based cancer registries   Life-tables                                               21                                             High
             2011                   Ardabil                                                                                                                                                                               

  ([@B29])   Movahedi M,\           2001-2005,\           3189              national cancer registry             Kaplan-Meier\                                             48                  27          19   16   13   High
             2009                   National                                                                     method                                                                                                   

  ([@B17])   Veisani Y,\            2006-2011,\           239               Hospital records                     Kaplan-Meier\                                             41                  17          13   10   6    High
             2013                   Sanandaj                                                                     method                                                                                                   

  ([@B30])   Atoof F,\              1995-2004,\           330               Hospital records                     Kaplan-Meier and Weibull Cure Models                                                      32        20   Medium
             2010                   Tehran                                                                                                                                                                                

  ([@B31])   Roshanaei Gh,\         2003 -- 2007,\        400               Hospital records                     Cox proportional hazards                                  74                  54          31   26   23   Medium
             2012                   Tehran                                                                                                                                                                                

  ([@B32])   Moghimi-Dehkordi B,\   2001-2005,\           442               Cancer Registration Center           Kaplan--Meier and Cox proportional hazard models          54                  30          24   18   16   Medium
             2007                   Tehran                                                                                                                                                                                

  ([@B33])   Barfei F,\             2007-2008,\           99                Hospital records                     Kaplan--Meier and Cox proportional hazard models          59                              40        18   Low
             2014                   Tehran                                                                                                                                                                                

  ([@B34])   Kashani H,\            1995-1999,\           330               Hospital records                     Kaplan--Meier and Cox proportional hazard models          62                  41          31   24   20   Medium
             2011                   Tehran                                                                                                                                                                                

  ([@B35])   Baeradeh NA,\          2006-2010,\           136               Hospital records                     Kaplan--Meier and Cox proportional hazard models          61                  45          31   26   25   Medium
             2015                   Yazd                                                                                                                                                                                  

  ([@B36])   Zeraati H,\            1995-1999,\           129               Hospital records                     A non-homogenous semi-Markovian stochastic process        67                              31        19   Medium
             2005                   Tehran                                                                                                                                                                                

  ([@B37])   Ghorbani S,\           2007-2012,\           430               Cancer Registration Center           Kaplan - Meier and\                                       64                  44          34   28   19   Medium
             2013                   Sari                                                                         univariate analysis                                                                                      

  ([@B14])   Roshanaei Gh,\         2003-2007,\           262               Hospital records                     Kaplan--Meier and Cox proportional hazard models          81                              45        30   Low
             2010                   Tehran                                                                                                                                                                                

  ([@B38])   Roshanaei Gh,\         2003-2007,\           93                Hospital records                     Kaplan--Meier models                                      42                              19        13   Medium
             2011                   Tehran                                                                                                                                                                                

  ([@B39])   Larizadeh MH,2013      2003-2011-Kerman      82                Hospital records                     Kaplan-Meier methods                                                                      53        22   Low

  ([@B40])   Gohari MR,\            2002-2007,\           232               Hospital records                     Kaplan-Meier methods                                      77                              26             Low
             2014                   Tehran                                                                                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Subcategories analysis of one to five survival rates by quality and data source

  **Subcategories**        **Survival Rate% (95% CI)**   **Heterogeneity**                                                              
  ------------------------ ----------------------------- ------------------- ----------- ----------- ----------- ----------- ---------- ----------
  Quality                  High                          51(50-51)           30(29-30)   23(22-23)   22(22-23)   15(14-15)   98.8       \<0.0001
  Medium                   63(61-65)                     42(39-44)           29(28-31)   24(22-26)   19(18-21)   89.6        \<0.0001   
  Low                      77(73-80)                     \-                  38(34-41)   22(13-31)   26(21-30)   87.5        \<0.0001   
  Data Source              Hospital records              67(65-68)           41(38-43)   27(26-29)   22(20-24)   16(14-17)   96.7       \<0.0001
  Cancer registry center   50(49-51)                     30(29-30)           23(23-24)   22(22-23)   15(15-16)   97.7        \<0.0001   
  Overall survival rate    52(52-53)                     31(30-31)           24(23-24)   22(22-23)   15(15-16)   95.6        \<0.0001   
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A significant heterogeneity among these studies was observed (heterogeneity statistic= 472.23, P\<0.001, I ^2^ = 91.8% (95% CI: 90.1--93.5) ([Fig. 3](#F3){ref-type="fig"}). Subgroup analysis was preformed to explore possible sources of heterogeneity among studies. Results of subgroup analysis showed a positive heterogeneity between quality of papers and data sources (P\< 0.001). [Table 2](#T2){ref-type="table"} presented these results; one- to five-year survival rate in publication with good quality is lower than articles with medium and low quality, respectively. Also one- to five-year survival rate in studies with cancer registry center data source is lower than hospital records. Results of meta-regression showed an association between publication year and one year survival rate, as well as five-year survival rate. Thus, year of publication is one of the main causes of variability in results of one- to five-year survival rate (Reg Coef= 0.016, p= 0.04) and (Reg Coef= 0.021, p= 0.049), respectively ([Fig. 4](#F3){ref-type="fig"}). According to results, an increasing rate of survival was observed across the study period. Also, we examined sample size as another explanatory factor to variability in results, which showed sample size was another reason for this inconsistency in results (Reg Coef= 0.00033, p= 0.027). Studies with a large sample size had a lower survival rate compared to studies with small sample size.

Results
=======

Using electronic searches, 102 papers were identified. After exclusion of reviews and duplicate articles and title screen, 43 separate publications remained for further appraisal. Remained articles, subsequent to abstract and full text review, we removed 17 publications according to the exclusion criteria and in the final data set consisted of 26 publications ([Fig. 1](#F1){ref-type="fig"}). Interpretation results of [table 2](#T2){ref-type="table"} shows attention to survival rate in patients with GC in Iran is increasing as if (64.4%) of final articles were published in 2011onwards. Primary data source for the greater part of studies (61.5) was hospital records.

The pooled participants in study were 29361 patients with GC ([Table 1](#T1){ref-type="table"}).

Twenty-four eligible papers, including 28949 patients were included in meta-analysis to estimate one-year survival rate. The overall one-year survival rate in patients with GC in Iran was 0.52 (95% CI: 0.52 to 0.53). There was a significant heterogeneity among these studies (heterogeneity statistic = 379.79, P\<0.001, I ^2^ = 98.5%, 95% CI 97.4--99.8) (Fig. 2).
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For Meta-analysis of five-year survival rate, we considered twenty-two publications with 28268 patients. The overall five year survival rate in patients with GC in Iran was 0.15 (95% CI, 0.15 to 0.16). A significant heterogeneity among these studies was observed (heterogeneity statistic= 472.23, P\<0.001, I ^2^= 91.8% (95% CI: 90.1--93.5) ([Fig. 3](#F2){ref-type="fig"}). Subgroup analysis was performed to explore possible sources of heterogeneity among studies. Results of subgroup analysis showed a positive heterogeneity between quality of papers and data sources (P\<0.001). [Table 2](#T2){ref-type="table"} presented these results; one- to five-year survival rate in publication with good quality is lower than articles with medium and low quality, respectively. Also, one- to five- year survival rate in studies with cancer registry center data source is lower than hospital records. Results of meta-regression showed an association between publication year and one-year survival rate, as well as five-year survival rate. Thus, year of publication is a cause of variability in results of one and five year survival rate (Reg Coef= 0.016, p= 0.04) and (Reg Coef= 0.021, p= 0.049), respectively ([Fig. 4](#F3){ref-type="fig"}). According to results, an increasing survival rate across the study period was observed. Also, we examined the sample size as other explanatory factor to variability in results and results showed sample size was another reason for this inconsistency in results (Reg Coef= 0.00033, p= 0.027). Studies with larger sample size had a lower survival rate.

Discussion
==========

In the present meta-analysis, we employed a large sample size to generate a reliable estimation of GC patient survival rates. We found a significant heterogeneity in our results, sources of which we explored using meta-regression and stratified subgroup analysis according to characteristics of the included studies. Our results showed that sample size and publication year were significant contributing factors to heterogeneity, where larger sample size and later year of publication were associated with a lower recorded rate of survival. In the present study, heterogeneity might result from different characteristics of patients, differing stages of disease progression, adjuvant treatment, duration of patient follow-up, or histological type. Due to limited resources in previous studies, we were unable to specify the role of these features that might contribute to disparate survival rates.

Ultimately, 26 studies were incorporated into our meta-analysis. Estimation of overall survival rate, and the one- through five-year rates of 24, 14, 23, 12, and 22 were 52%, 31%, 24%, 22%, and 15%, respectively. These numbers indicate that more than half of GC deaths occurred within the first year following diagnosis, and another 30% took place during the second year. It is the greatest difficulty about patients with GC in Iran versus worthwhile clinical finding to correct rational strategies to address these problems. Various histological and demographic factors such as age, gender, surgery and treatment type, cancer site, grade of tumor, as well as metastasis have been found to impact the rate of GC survival in Iran. An investigation into risk factors associated with GC may help to reduce the probability of death in patients. Other strategies include a comprehensive follow-up plan for patients with premature signs of the disease, as well as the study and application of suitable treatments ([@B5]).

Results of the present study suggest that the overall five-year survival rate in Iran (15%) is lower than the survival rate in countries such as China (29.6%), the United States (37%), Switzerland (22%), France (30%), and Japan (40-60%)([@B1], [@B13], [@B41]). We classify possible explanations for this inconsistency into three main factors: cancer stage at diagnosis, patient characteristics, and treatment process. In most studies, late diagnosis was related to a lower survival rate, while diagnosis at an early stage was determined to be the most important predictive factor for survival. In terms of patient characteristics, a lower survival rate was associated with older and socioeconomically disadvantaged patients, as well as those who did not respond favorably to the treatment. Finally, mixed therapies incorporating chemotherapy, radiotherapy, and surgery were shown to strongly enhance the rate of survival.

As mentioned, a nationwide lack of cancer registry centers presents an additional obstacle to investigating GC in Iran, and the results of this study demonstrate this limitation. Although 64.4% of sources were derived from cancer registry data, the overall survival rates were lower than the results obtained from hospital records. Hospital records in developing countries are generally limited because data are missing, riddled with errors, or not deliberately gathered for the purpose of later scrutiny. Additionally, eligible patients for the present study were from one distinct hospital and could not represent all coverage patients in a population.

The present meta-analysis expanded the number of participants to produce reliable and generalizable results regarding the GC survival rate in Iran. Limitations of this study were heterogeneity among 26 included studies, a scarcity of abstracts, and the inclusion of only 11 studies out of 102 gathered due to lack of available survival statistics. These limitations could impact the findings of this analysis.

According to our research, more than half of GC deaths occurred in the first year after diagnosis, and another 30% took place during the second year. These findings support previous reports that suggest a poor diagnosis is the greatest challenge to GC patients in Iran.

Note
====
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